Merkel Cell Carcinoma of the Eyelid
What Merkel Cell Carcinoma Is
Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer that grows quickly and can spread early. It forms from Merkel cells, which are specialized cells in the top layer of skin involved in touch sensation. When those cells turn malignant, they form a fast-growing nodule that looks like a harmless bump at first.
About half of MCC cases appear on the head and neck, where sun exposure is highest. 5% to 10% of MCC cases involve the eyelid or periocular region, per EyeWiki data. Fewer than 2,000 cases of MCC occur each year in the United States, per NCI/NIH 2017 data.
MCC typically affects older adults, usually in their 70s or 80s, and is more common in fair-skinned people with significant sun exposure. Immunosuppression (from organ transplant medications, HIV, chronic lymphocytic leukemia, or other causes) significantly increases the risk. The Merkel cell polyomavirus is linked to a majority of MCC cases.
MCC has a much higher rate of recurrence and metastasis than basal cell or squamous cell carcinoma. Catching it early dramatically changes outcomes. Because it often looks innocent, early diagnosis requires a high index of suspicion and willingness to biopsy unusual lesions in older patients.
What It Looks Like
MCC typically presents as a painless, rapidly enlarging, firm, red to violaceous (purple-red) nodule. The surface is usually smooth and may look shiny. There is often no ulceration in early stages. The lesion can double in size in weeks, which helps distinguish it from slower-growing cancers.
MCC is often misdiagnosed as a chalazion, basal cell carcinoma, epidermal cyst, or other benign lesion. It does not have the classic pearly edge of BCC or the scaling of SCC. Many eyelid MCCs are treated for weeks as a chalazion before the correct diagnosis is made. This is why any rapidly growing, painless, non-resolving eyelid nodule in an older or immunocompromised patient needs biopsy.
A useful acronym called AEIOU highlights features that should raise suspicion:
- A: Asymptomatic (painless)
- E: Expanding rapidly
- I: Immunosuppression
- O: Older than 50
- U: UV-exposed, fair skin
A lesion with three or more of these features deserves prompt biopsy.
Diagnosis
Diagnosis requires a biopsy. Either an excisional biopsy (removing the whole lesion) or an incisional biopsy (taking a piece) confirms the cancer. Pathologists examine the sample using standard histology and immunohistochemistry. MCC cells stain positive for cytokeratin 20 (CK20) in a characteristic dot-like pattern and for neurofilament. These markers help distinguish MCC from other small round blue cell tumors.
Once MCC is confirmed, staging is urgent because of the high risk of spread. Staging typically includes:
- Physical exam with careful lymph node evaluation
- Imaging: CT, MRI, or PET-CT to check for regional and distant spread
- Sentinel lymph node biopsy for primary tumors without clinically evident nodal disease
MCC care involves several specialists from the start:
- Oculoplastic surgeon for eyelid reconstruction
- Medical oncologist for systemic therapy decisions
- Radiation oncologist for adjuvant radiation planning
- Head-and-neck surgeon or general surgical oncologist for lymph node dissection when indicated
Treatment Approach
Wide local excision is the primary treatment. Recommended margins are approximately 1 centimeter for lesions under 2 centimeters and 2 centimeters for larger lesions, per EyeWiki guidance. On the eyelid, achieving these margins without sacrificing the eye itself is challenging. Surgeons often use Mohs micrographic surgery or frozen-section controlled excision to balance oncologic adequacy and tissue preservation.
Radiation to the primary site and regional lymph node basin is standard for most eyelid MCC. Radiation reduces local recurrence and may improve survival. The treatment course typically spans several weeks. Side effects include skin redness, dry eye, lash loss, and temporary lid swelling, which the radiation oncologist mitigates with careful planning.
Sentinel lymph node biopsy is recommended for clinically node-negative disease. If sentinel nodes are positive, a completion lymph node dissection or radiation to the nodal basin follows. For patients with palpable nodes, definitive lymph node dissection with or without radiation is standard.
Immune checkpoint inhibitors have transformed treatment for advanced MCC. The FDA approved avelumab (anti-PD-L1) in March 2017 as the first immunotherapy for metastatic MCC, with an overall response rate of 33% in previously treated patients, per FDA and NCI data. Pembrolizumab is also used in advanced disease. Immunotherapy is increasingly considered even in earlier-stage disease as part of clinical trials.
Standard 1 to 3 centimeter margins are not feasible on the eyelid without removing the eye. Oculoplastic surgeons and Mohs dermatologists coordinate to achieve the best oncologic result while preserving vision and function. Reconstruction follows the same size-based principles as for other eyelid cancers.
Reconstruction
Reconstruction is often staged to ensure clean margins are confirmed before the final rebuild. Some patients have a temporary protective patch or skin graft while awaiting margin confirmation, with definitive reconstruction a few days later. Adjuvant radiation influences timing: reconstruction is usually done before radiation to avoid healing delays.
Options include:
- Direct closure for small defects after clean margins
- Local flaps such as Tenzel semicircular flap
- Tarsoconjunctival grafts from the opposite upper lid
- Hughes flap for large lower lid defects
- Cutler-Beard flap for large upper lid defects
- Full-thickness skin grafts from behind the ear
Reconstruction prioritizes eye closure and corneal protection over cosmetic symmetry. Radiation sometimes changes how tissue heals, so the surgeon chooses techniques with good blood supply. Minor revisions may follow months later once radiation is complete and the tissue has settled.
Prognosis and Survival
Prognosis depends strongly on stage at diagnosis. Per EyeWiki and JAMA Ophthalmology 2014 data, 5-year survival is approximately 97% in node-negative patients, 52% in node-positive patients, and less than 10% at 3 years in patients with distant metastasis.
Even after complete treatment, recurrence is common, especially in the first 2 years. Most recurrences appear as new nodules at the surgical site, in the draining lymph node basin, or as distant metastases. Close surveillance catches recurrences early when treatment options are still broad.
Immunotherapy has improved survival for advanced MCC. Durable responses (lasting over a year) occur in a meaningful percentage of patients. Research into earlier use of immunotherapy and combination regimens is active, and clinical trials offer access to newer approaches.
Follow-Up Plan
Because of the high recurrence risk, follow-up is intensive, especially in the first 2 years. A typical plan includes:
- Clinical exam every 3 to 4 months for 3 years, then every 6 months
- Imaging (PET-CT or CT of the neck and chest) every 6 to 12 months based on stage
- Full-body skin check with dermatology every 6 months
- Lymph node ultrasound in some protocols for sensitive nodal surveillance
Between visits, check for new nodules near the surgery site, changes in the eye, enlarged lymph nodes, unexplained weight loss, or persistent pain anywhere in the body. Early reporting of concerning symptoms keeps treatment options open.
After 5 years of no recurrence, visits typically space to annually. Because MCC survivors remain at higher risk of other skin cancers and sometimes other malignancies, regular dermatology and primary care follow-up continues indefinitely.
Prevention and Risk Reduction
Consistent UV protection reduces skin damage and may lower risk of MCC and other skin cancers. Strategies include:
- Daily mineral sunscreen on the face and eyelid area
- UV-blocking wraparound sunglasses
- Wide-brimmed hat outdoors
- Avoiding peak sun hours and tanning beds
Patients on chronic immunosuppression benefit from closer skin surveillance. If possible, minimizing immunosuppressive doses under the direction of the managing physician may reduce skin cancer risk. Dermatology follow-up every 6 months is reasonable in high-risk patients.
Full-body skin checks with a dermatologist identify early suspicious lesions. For older patients with significant sun damage, twice-yearly visits may be appropriate. Any new, rapidly growing lesion warrants biopsy.
Living with a Merkel Cell Carcinoma Diagnosis
Receiving an aggressive cancer diagnosis is stressful. Many patients feel shock, fear, and uncertainty about outcomes. Oncology social workers, support groups, and mental health counselors help patients and families cope. Cancer centers often have dedicated programs for patients and caregivers.
Surgery, radiation, and immunotherapy each have side effects. Surgery and radiation produce local changes in the skin and eye area. Immunotherapy can cause immune-related reactions in various organs that need monitoring. Supportive care from the oncology team manages these along the way.
Most patients continue meaningful daily activities during MCC treatment with adjustments. Driving may be limited after certain surgeries. Work and travel are possible between treatments for many patients, with planning around radiation and infusion schedules.
Common Questions About Merkel Cell Carcinoma
Early MCC can look like a benign bump, and chalazion is very common. Most clinicians correctly diagnose MCC after it fails to respond to warm compresses or recurs after drainage. The AEIOU features and a clinician's awareness of MCC are the best defense against diagnostic delay. If you were treated for a bump that continued to grow, you did the right thing to return for further evaluation.
No. Although MCC is associated with the Merkel cell polyomavirus in many cases, MCC itself is not transmitted person to person. The virus is common in the general population and only rarely triggers cancer. You cannot spread MCC to family members or contacts.
Yes, recurrence is possible, especially in the first 2 years. Patients who have had MCC also have a higher risk of other skin cancers. Ongoing surveillance with your eye doctor, dermatologist, and oncologist catches recurrences early. Report new lumps, skin changes, or symptoms promptly.
Most eyelid MCC cases do not require removing the eye. Careful surgical planning, Mohs-type techniques, and adjuvant radiation preserve the eye in the majority of cases. Very advanced cases with deep orbital invasion may require more extensive surgery, but this is uncommon with early diagnosis.
Because MCC is aggressive, treatment typically starts within 2 to 4 weeks of diagnosis. Staging, multidisciplinary consultation, and surgical planning happen in that window. Patients often receive an expedited schedule because of the recurrence risk with any delay.
For MCC, clinical trials often offer access to combination immunotherapy, novel agents, or adjuvant approaches for earlier-stage disease. Cancer centers with MCC expertise can help identify relevant trials. Your oncologist discusses the risks, benefits, and eligibility criteria.
Act Quickly on a Suspicious Nodule
A rapidly growing, painless eyelid nodule in an older or immunocompromised patient is a potential MCC until proven otherwise. An oculoplastic specialist can biopsy the lesion, coordinate pathology, and engage the multidisciplinary team needed for MCC. Early action saves lives. Schedule an urgent evaluation today.